• Genfit expanded its collaboration with Labcorp by adding Labcorp OnDemand access for NASHnext, a blood test based on Genfit’s NIS4 technology.
• The move broadens US patient access through physician-validated online ordering, aiming to accelerate adoption for identifying “at-risk” MASH patients.
• Genfit positioned the rollout as a step toward wider reimbursement coverage, including a potential Medicare and Medicaid decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606081200OMX_____CNEWS_FR_GNW1001186540_fr) on June 08, 2026, and is solely responsible for the information contained therein.